Showing results (41-50 of 143) with videos related to

Sort By:
Pageof 15
Blood|October 18, 2002
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT)Loïc Fouillard, Myriam Labopin, Norbert-Claude Gorin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2021
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid LeukemiaPierre-Yves Dumas, Arnaud Villacreces, Amélie V Guitart, et al.
Cancer|September 17, 2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AMLJorge E Cortes, Stuart L Goldberg, Eric J Feldman, et al.
Blood|August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseFrancis Giles, Norbert Vey, Daniel DeAngelo, et al.
Cancer|March 29, 2016
Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTomasz Czerw, Myriam Labopin, Norbert-Claude Gorin, et al.
Cancers|January 21, 2022
Autophagy Targeting and Hematological Mobilization in FLT3-ITD Acute Myeloid Leukemia Decrease Repopulating Capacity and Relapse by Inducing Apoptosis of Committed Leukemic CellsMarine Dupont, Mathilde Huart, Claire Lauvinerie, et al.
British Journal of Haematology|April 22, 2005
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remissionEric Jourdan, Françoise Rigal-Huguet, Gerald Marit, et al.
Blood|May 3, 2002
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML IntergroupStéphanie Nguyen, Thierry Leblanc, Pierre Fenaux, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 7, 2012
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITDGaëlle Labouré, Stéphanie Dulucq, Myriam Labopin, et al.
Cancer Medicine|July 27, 2022
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMTArnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Pageof 15